AbbVie Inc.
NYSEABBV has given back a few dollars from last week's peak but remains up nearly 5% on the week at $225.42, and the most interesting development is not the price — it's a sharp divergence between options traders leaning more bullish than they have in months and a short position that has quietly accelerated to its fastest build in at least six weeks. The options shift is the standout…
ABBV cost to borrow jumps to 0.48%, up 128% in one week as short interest climbs 7.9% over the same period.
Snapshot as of 22 Jun 2026
A new long-form analysis for ABBV this week — anomalies vs the company's own history, peer comparisons, news context, and the full data picture. Premium subscribers only.
Read on ORTEX →Sign up for premiumABBV has given back a few dollars from last week's peak but remains up nearly 5% on the week at $225.42, and the most interesting development is not the price — it's a sharp divergence between options traders leaning…
ABBV enters the first week of June trading at $215.40, up roughly 1% on the week, with options positioning still leaning bullish and the Street's consensus target implying a further 17% upside — even as short sellers…
ABBV heads into late May with a notable divergence: options traders have turned more bullish than they've been all year, even as short sellers quietly rebuild positions and the pipeline debate grows louder. The options…
ABBV heads into mid-May on the back of a strong Q1 print — and the market is rewarding it, with the stock up 2.5% on Tuesday to close at $207.86. The real story this week is analyst conviction following the April 29…
ABBV heads into its May 8 Q1 earnings with the analyst community firmly in the bull camp — and quietly raising the bar. The clearest signal ahead of the print is the strength of recent analyst upgrades. Morgan Stanley…
ABBV delivered what management called an "excellent start to 2026" on April 29, with immunology and neuroscience strength driving a beat that lifted shares 3.1% on the day. Yet even as the stock reclaimed $203.89 and…
AbbVie reports Wednesday with short positioning at a three-week low. The options market shows mild bearish tilt while analyst activity remains mixed. Short interest stands at 1.10% of float as of April 23. That's down…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for ABBV — free to start on ORTEX.
Sign up for free →Open ABBV on ORTEX